Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ivermectin for children with mild to moderate atopic dermatitis
IRCT20240724062525N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivermectin in atopic dermatitis (AD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Efficacy and Side effects. Started Jun 2026; status: completed.
02
Drugs
ivermectin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on IRCT20240724062525N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240724062525N1.